The therapeutic effect of transcatheter arterial chemoembolization combined with toripalimab in 88 patients with advanced primary liver cancer

Abstract

Abstract: Objective To explore the therapeutic effect of transcatheter arterial chemoembolization (TACE) combined with toripalimab in patients with advanced primary liver cancer. Methods 88 patients with advanced primary liver cancer admitted to the Department of Oncology of Wuzhou People's Hospital from January 2020 to December 2022 were randomly divided into an observation group and a control group according to a random number table. The control group was treated with TACE, and the observation group was treated with TACE and toripalimab. The recent efficacy, serum liver biochemical indicators, tumor marker levels, and adverse events were compared between the two groups. The survival curve was conducted and compared by Kaplan-Meier method. Results The baseline data of the two groups of patients before treatment were not heterogeneous (P>0.05). After treatment, the Objective remission rate, disease control rate, and complete pathological remission rate of the observation group were 61.36%, 95.45%, and 59.09%, respectively, which were significantly higher than those in the control group (36.36%, 77.27%, and 36.36%, respectively, P<0.05). The serum alanine aminotransferase, aspartate aminotransferase, total bilirubin, and tumor markers such as carcinoembryonic antigen, alpha-fetoprotein, and α-L-fucosidase in the observation group were significantly lower than those in the control group (P<0.05). The incidence of adverse events in the control group and observation group was 22.73% and 38.64%, respectively, without statistically significant difference (P>0.05). At the end of follow-up, the survival rates of the observation group was 65.91% (29/44), which was significantly higher than the rate of 43.18% (19/44), in the control group (χ²=4.900, P=0.027). Conclusion TACE combined with toripalimab has significant therapeutic effect in patients with advanced primary liver cancer and is suitable for further promotion and application.

Key words: Transcatheter arterial chemoembolization, Toripalimab, Primary liver cancer, Clinic effect, Prognosis

JIANG Shi-wu, PENG Xiao-yan, CHEN Jun-yuan, FENG Fei-yao, LIU Mei-ling. The therapeutic effect of transcatheter arterial chemoembolization combined with toripalimab in 88 patients with advanced primary liver cancer[J]. Chinese Hepatolgy, 2024, 29(6): 676-680.

References

[1] 刘二丽, 李博群, 黄盈婷, 等. 原发性肝癌四种治疗策略的成本效果比较[J]. 肝脏,2023,28(2):193-199.
[2] Ding X, Sun W, Li W, et al. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study[J]. Cancer,2021,127(20):3782-3793.
[3] Miura J T, Gamblin T C. Transarterial chemoembolization for primary liver malignancies and colorectal liver metastasis[J]. Surg Oncol Clin N Am,2015,24(1):149-166.
[4] West H J, Jin J O. Transarterial chemoembolization[J]. JAMA Oncol,2015,1(8):1178.
[5] Yang Y, Pan J, Wang H, et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)[J]. Cancer Cell,2023,41(6):1061-1072.
[6] Shen L, Kato K, Kim S, et al. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study[J]. J Clin Oncol,2022,40(26):3065-3076.
[7] Qin S, Kudo M, Meyer T, et al. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial[J]. JAMA Oncol,2023,9(12):1651-1659.
[8] 中国抗癌协会肝癌专业委员会, 中华医学会肝病学分会肝癌学组, 中国抗癌协会病理专业委员会, 等. 原发性肝癌规范化病理诊断指南(2015年版)[J]. 中华肝胆外科杂志,2015,21(3):145-151.
[9] Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer,2009,45(2):228-247.
[10] Hellmann M D, Chaft J E, William W N J, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint[J]. Lancet Oncol,2014,15(1):42-50.
[11] Basch E, Becker C, Rogak L J, et al. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)[J]. Clin Trials,2021,18(1):104-114.
[12] Storandt M H, Mahipal A, Tella S H, et al. Systemic therapy in advanced hepatocellular carcinoma: Patient selection and key considerations[J]. J Hepatocell Carcinoma,2022,9:1187-1200.
[13] Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Gut,2020,69(8):1492-1501.
[14] Zhang L, Hao B, Geng Z, et al. Toripalimab: the first domestic anti-tumor PD-1 antibody in China[J]. Front Immunol,2021,12:730666.
[15] Keam S J. Toripalimab: First global approval[J]. Drugs,2019,79(5):573-578.
[16] Lu H, Liang B, Xia X, et al. Efficacy and safety analysis of TACE+Donafenib+Toripalimab versus TACE+Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study[J]. BMC Cancer,2023,23(1):1033.
[17] Liu H, Guo L, Zhang J, et al. Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy[J]. MAbs,2019,11(4):681-690.
[18] Tang B, Chi Z, Guo J. Toripalimab for the treatment of melanoma[J]. Expert Opin Biol Ther,2020,20(8):863-869.
[19] Jiang M, Zhang C, Hu Y, et al. Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma[J]. Oncologist,2022,27(11):856-869.